A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
Saved in:
| Title: | A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. |
|---|---|
| Authors: | Heussler H; Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children's Health Queensland, Brisbane, Australia.; Centre for Child Health Research, University of Queensland, Brisbane, Australia., Cohen J; Fragile X Alliance Inc. and Genetic Clinics Australia, Melbourne, Australia., Silove N; The Children's Hospital at Westmead, Sydney, Australia., Tich N; Zynerba Pharmaceuticals, Devon, PA, 19333, USA. TichN@Zynerba.com., Bonn-Miller MO; Canopy Growth Corporation, Smith Falls, Ontario, V7A 0A8, Canada., Du W; Clinical Statistics Consulting, Blue Bell, PA, 19422, USA., O'Neill C; Zynerba Pharmaceuticals, Devon, PA, 19333, USA., Sebree T; Zynerba Pharmaceuticals, Devon, PA, 19333, USA. |
| Source: | Journal of neurodevelopmental disorders [J Neurodev Disord] 2019 Aug 02; Vol. 11 (1), pp. 16. Date of Electronic Publication: 2019 Aug 02. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101483832 Publication Model: Electronic Cited Medium: Internet ISSN: 1866-1955 (Electronic) Linking ISSN: 18661947 NLM ISO Abbreviation: J Neurodev Disord Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1866-1955 |
|---|---|
| DOI: | 10.1186/s11689-019-9277-x |
